Trinity Biotech (TRIB) said Friday it acquired EpiCapture, which is developing a test to monitor the risk of prostate cancer.
Trinity said it bought EpiCapture for an initial consideration of about $3 million, with an additional $0.5 million linked to the achievement of milestones.
The initial consideration was paid via the issuance of about 1.7 million American depository shares in Trinity, the company said.
Shares were 1% higher in recent premarket activity.
Price: 1.8500, Change: +0.02, Percent Change: +1.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments